Zai Lab (NASDAQ:ZLAB) Director William Lis Sells 8,506 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director William Lis sold 8,506 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $25.00, for a total value of $212,650.00. Following the sale, the director directly owned 41,931 shares in the company, valued at $1,048,275. This trade represents a 16.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

William Lis also recently made the following trade(s):

• On Monday, June 22nd, William Lis sold 7,040 shares of Zai Lab stock. The shares were sold at an average price of $18.09, for a total value of $127,353.60.

Zai Lab Trading Up 2.1%

Shares of ZLAB stock traded up $0.54 on Thursday, reaching $26.03. The company’s stock had a trading volume of 1,041,801 shares, compared to its average volume of 843,216. The stock’s fifty day simple moving average is $19.22 and its 200-day simple moving average is $19.39. Zai Lab Limited Unsponsored ADR has a 1 year low of $15.96 and a 1 year high of $36.77. The company has a market capitalization of $2.96 billion, a price-to-earnings ratio of -15.22 and a beta of 0.78.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($0.50) earnings per share (EPS) for the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. The business had revenue of $106.31 million for the quarter. Equities research analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.17 earnings per share for the current year.

Institutional Investors Weigh In On Zai Lab

A hedge fund recently raised its position in Zai Lab stock. SG Americas Securities LLC lifted its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. Institutional investors own 41.65% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ZLAB. Citigroup increased their price target on shares of Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 7th. Zacks Research raised Zai Lab from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen cut Zai Lab from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Zai Lab presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.20.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.